Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation

doi:10.1136/jclinpath-2012-200786

CNU IR > Pharmacy and Science > Dept. of Health and Nutrition (including master's program) > Periodical Articles > Item 310902800/27597

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/27597

Title:	Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation
Authors:	Lin, Ching-Yih Tian, Yu-Feng Wu, Li-Ching Chen, Li-Tzong Lin, Li-Ching Hsing, Chung-Hsi Lee, Sung-Wei Sheu, Ming-Jen Lee, Hao-Hsien Wang, Yu-Hui Shiue, Yow-Ling Wu, Wen-Ren Huang, Hsuan-Ying Hsu, Han-Ping Li, Chien-Feng Chen, Shang-Hung Chen, Li-Tzong�
Contributors:	保健營養系
Keywords:	Chromatin Remodeling Factor Preoperative Radiotherapy Sphincter Preservation Functional-Analysis Tumor Response Acute Toxicity Dna-Damage Carcinoma Overexpression Survival
Date:	2012-08
Issue Date:	2014-03-21 16:14:44 (UTC+8)
Publisher:	Bmj Publishing Group
Abstract:	Aims Neoadjuvant chemoradiation therapy (CRT) is an increasingly used therapeutic strategy for rectal cancer. Clinically, it remains a major challenge to predict therapeutic response and patient outcome after CRT. Rsf-1 (HBXAP), a novel nuclear protein with histone chaperon function, mediates ATPase-dependent chromatin remodelling and confers tumour aggressiveness and predicts therapeutic response in certain carcinomas. However, the expression of Rsf-1 has never been reported in rectal cancer. This study examined the predictive and prognostic impacts of Rsf-1 expression in patients with rectal cancer following neoadjuvant CRT.Methods Rsf-1 immunoexpression was retrospectively assessed for pre-treatment biopsies of 172 rectal cancer patients without initial distant metastasis. All of them were treated with neoadjuvant CRT followed by surgery. The results were correlated with the clinicopathological features, therapeutic response, tumour regression grade and metastasis-free survival (MeFS), local recurrent-free survival and disease-specific survival.Results Present in 82 cases (47.7%), high-expression of Rsf-1 was associated with advanced pre-treatment tumour status (T3, T4, p=0.020), advanced post-treatment tumour status (T3, T4, p<0.001) and inferior tumour regression grade (p=0.028). Of note, high-expression of Rsf-1 emerged as an adverse prognosticator for diseases-specific survival (p=0.0092) and significantly predicted worse MeFS (p=0.0006). Moreover, high-expression of Rsf-1 also remained prognostic independent for worse MeFS (HR 2.834; p=0.0214).Conclusions High-expression of Rsf-1 is associated with poor therapeutic response and adverse outcome in rectal cancer patients treated with neoadjuvant CRT, which confers tumour aggressiveness and therapeutic resistance through chromatin remodelling and represents a potential prognostic biomarker in rectal cancer.
Relation:	Journal of Clinical Pathology, 65(8), 687-692
Appears in Collections:	[Dept. of Health and Nutrition (including master's program)] Periodical Articles

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	1925	View/Open

Loading...